dc.contributor.author | Aydın, Sabin Göktaş | |
dc.contributor.author | Ölmez, Ömer Fatih | |
dc.contributor.author | Selvi, Oğuzhan | |
dc.contributor.author | Geredeli, Çağlayan | |
dc.contributor.author | Özden, Ferhat | |
dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Açıkgöz, Özgür | |
dc.contributor.author | Karcı, Ebru | |
dc.contributor.author | Kutlu, Yasin | |
dc.contributor.author | Hamdard, Jamshid | |
dc.contributor.author | Aydın, Ahmet | |
dc.date.accessioned | 2024-06-04T11:55:51Z | |
dc.date.available | 2024-06-04T11:55:51Z | |
dc.date.issued | 2024 | en_US |
dc.identifier.citation | Aydın, S. G., Ölmez, Ö. F., Selvi, O., Geredeli, Ç., Özden, F., Bilici, A. ... Aydın, A. (2024). The prognostic role of mismatch repair status and CDX-2 expression with inflammatory markers and pathological risk factors in stage ıı and ııı colon cancer: Multicenter real-life data. Journal of Gastrointestinal Cancer, 55(1), 227-236. http://dx.doi.org/10.1007/s12029-023-00953-0 | en_US |
dc.identifier.issn | 1941-6628 | |
dc.identifier.issn | 1941-6636 | |
dc.identifier.uri | http://dx.doi.org/10.1007/s12029-023-00953-0 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/12563 | |
dc.description.abstract | Objective: Colorectal cancer is common worldwide, and adjuvant treatment’s benefit is still controversial. We designed this study to determine the role of MSI and CDX-2 status determined by immunohistochemistry (IHC) combined with the inflammatory markers and pathological parameters in predicting disease recurrence in stage II and III colon cancer. Methods: A total of 226 stage II/III colon cancer patients with a median age of 59 years who underwent initial surgery were included in this retrospective study. The pathologic assessment of MSI and CDX-2 was performed twice by immunohistochemistry (IHC) and two different pathologists. No staining/weak staining below 10% of the tumor was accepted as CDX-2 negative, and any MSI clones with weak staining below 10% were accepted as MSI-H. The laboratory parameters were noted at the initial diagnosis. Results: One hundred twenty-one and 105 patients were diagnosed with stage III and II colon cancer. 58.0% of patients were male, 46 (20.4%) of tumor tissue were MSS, and 17 (7.5%) were CDX-2 negative. One hundred twenty-nine tumors were localized in the right colon. Disease recurrence was significantly correlated with tumor localization, CDX-2 status, stage at diagnosis, and preoperatively median CRP and CEA levels. DFS rates for MSS patients with CDX-2 negative and positive were 36.7% and 98.1%, respectively [p < 0.001]. There was no significant correlation between MSI status and CDX-2 status. MSI status, the presence of adjuvant treatment, and systemic inflammatory markers were not significant prognostic factors for DFS. CDX-2 status [HR:0.08, CI 95% 0.03–0.17, p < 0.001 HR: 1.7, CI 95% 1.1–3.0, p = 0.03], disease stage [HR:2.6, CI 95% 1.43–4.74], and preoperatively CEA levels [HR:4.1 CI 95% 2.18–785, p < 0.001 were independent significant prognostic factors for DFS. Conclusion: CDX-2 loss was an independent prognostic factor for DFS and disease recurrence in early-stage colon cancer. MSS patients with CDX-2 loss had significantly worse survival outcomes, and this might be the reason for deciding on adjuvant chemotherapy. | en_US |
dc.language.iso | eng | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | CDX-2 | en_US |
dc.subject | Colon Cancer | en_US |
dc.subject | Disease-Free Survival | en_US |
dc.subject | Inflammatory Marker | en_US |
dc.subject | MSI | en_US |
dc.title | The prognostic role of mismatch repair status and CDX-2 expression with inflammatory markers and pathological risk factors in stage ıı and ııı colon cancer: Multicenter real-life data | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of Gastrointestinal Cancer | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-0077-6971 | en_US |
dc.authorid | 0000-0002-2901-4671 | en_US |
dc.authorid | 0000-0003-2715-4002 | en_US |
dc.authorid | 0000-0001-8802-6376 | en_US |
dc.authorid | 0000-0002-5823-1704 | en_US |
dc.authorid | 0000-0002-8610-768X | en_US |
dc.identifier.volume | 55 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.startpage | 227 | en_US |
dc.identifier.endpage | 236 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1007/s12029-023-00953-0 | en_US |
dc.institutionauthor | Göktaş Aydın, Sabin | |
dc.institutionauthor | Ölmez, Ömer Fatih | |
dc.institutionauthor | Özden, Ferhat | |
dc.institutionauthor | Bilici, Ahmet | |
dc.institutionauthor | Açıkgöz, Özgür | |
dc.institutionauthor | Karcı, Ebru | |
dc.institutionauthor | Kutlu, Yasin | |
dc.institutionauthor | Hamdard, Jamshid | |
dc.institutionauthor | Aydın, Ahmet | |
dc.identifier.wos | 001014471300001 | en_US |
dc.identifier.scopus | 2-s2.0-85162997296 | en_US |
dc.identifier.pmid | 37347353 | en_US |
dc.identifier.scopusquality | Q3 | en_US |